Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Phase 3

• Conditions: Adult Acute Lymphoblastic Leukemia
• Interventions: Drug: Vincristine Sulfate; Drug: Vincristine Sulfate Liposome

• Registration Number: NCT02072785
• Lead Sponsor: Nanjing Luye Sike Pharmaceutical Co., Ltd.

Brief Summary

The purpose of this study is to determine whether vincristine sulfate liposome could reduce less peripheral neuropathy than vincristine sulfate,and be as effective as vincristine sulfate in adults with Naïve Acute Lymphoblastic Leukemia.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-06
• Status Verified: 2013-11
• Study First Submitted: 2014-02-25
• Study First Submitted QC: 2014-02-26
• Study First Posted: 2014-02-27
• Last Update Submitted: 2014-02-27
• Last Update Posted: 2014-03-03
• Primary Completion: 2017-02
• Study Completion: 2017-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

• De novo untreated ALL patients diagnosed by the bone marrow morphology, immunophenotype.

• 65 ≥ Age (years) ≥ 18 , male or female,

• ECOG Performance status of 0, 1, or 2.

• Patients must fulfill the following laboratory values

  1. Total bilirubin ≤2 ULN (corrected for same age)
  2. AST and ALT ≤3 ULN ( corrected for same ages)
  3. Serum creatinine ≤2 ULN (corrected for same age)

• Didn't receive any of the following treatments within 4 weeks before inclusion: chemotherapy, radiotherapy, replacement therapy, operation, long term of glucocorticoid therapy（>5 days）.

• No neurological disorders, no nerve or muscle injury (motor and sensory nerve).

• Patient must sign the informed consent and obey the protocol.

Exclusion Criteria

• Atopy or allergic to multiple medicines or excipients.
• With serious complications that affect compliance.
• Serious organ dysfunctions or central nervous system disorders.
• Mixed phenotype acute leukemia, (T-B).
• Burkitt lymphoma/leukemia.
• Suspected or confirmed central nervous system leukemia.
• Diabetes.
• Received antifungal treatment with triazole agents within 1 month before inclusion.
• Reliance of antipyretic and analgesic medicines or psychotropic medicines.
• Undergoing or has undergone other clinical trials in 4 weeks before inclusion.
• Pregnant women, women of breast feeding or childbearing potential without contraception.
• Psychological disorders that affect signing consent.
• The investigators believe that patients who are not suitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vincristine Sulfate	Vincristine Sulfate	Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22. Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent.
Vincristine Sulfate Liposome	Vincristine Sulfate Liposome	Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22. Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection.

Primary Outcome Measures

Name	Time	Method
Overall response rate(objectives (ORR)	up to 35 days	ORR=CR+CRi CR(Complete response); 1. No circulating blasts or extramedullary disease, No lymphadenopathy,splenomegaly,skin/gum infiltration/testicular mass/CNS involvement; 2. Trilineage hematopoiesis(TLH)and \<5% blast in bone marrow; 3. ANC\>1000/microl; 4. Platelets\>100,000/microl; CRi(Complete response with incomplete recovery of counts) Recovery of platelets but\<100,000 or ANC is \<1000/microl
Incidence of General peripheral neuropathy	A week before enrollment. one,two,three and four weeks after the start of induction chemotherapy	Chemotherapy-induced peripheral neuropathy was evaluated By Total Neuropathy Score clinical Version(TNSc).; If the score of any item of TNSc at anytime after the start of induction chemotherapy is higher than the baseline,it is considered that peripheral neuropathy occurs.

Trial Locations

Locations (1)

Hospital of Blood Diseases, Chinese Academy of Medical Sciences; 🇨🇳 Tianjin, China